WallStSmart

Cronos Group Inc (CRON)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 9028% more annual revenue ($14.56B vs $159.53M). CRON leads profitability with a -1.1% profit margin vs -2.0%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

CRON

Hold

45

out of 100

Grade: D+

Growth: 10.0Profit: 2.0Value: 5.0Quality: 9.0
Piotroski: 5/9Altman Z: 14.19

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 0.55

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRON5 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
40.1%10/10

Revenue surging 40.1% year-over-year

EPS GrowthGrowth
126.8%10/10

Earnings expanding 126.8% YoY

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
14.1910/10

Safe zone — low bankruptcy risk

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Areas to Watch

CRON4 concerns · Avg: 1.8/10
Market CapQuality
$1.05B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-0.2%2/10

ROE of -0.2% — below average capital efficiency

Profit MarginProfitability
-1.1%1/10

Currently unprofitable

Operating MarginProfitability
-1.1%1/10

Operating margin of -1.1%

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : CRON

The strongest argument for CRON centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 40.1% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : CRON

The primary concerns for CRON are Market Cap, Return on Equity, Profit Margin.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

CRON profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.

CRON carries more volatility with a beta of 1.25 — expect wider price swings.

CRON is growing revenue faster at 40.1% — sustainability is the question.

VTRS generates stronger free cash flow (348M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cronos Group Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.

Visit Website →

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?